Agios Pharmaceuticals (AGIO) Competitors

Verona Pharma (NASDAQ:VRNA) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, community ranking, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Is VRNA or AGIO more profitable?

Agios Pharmaceuticals has a net margin of 1,845.92% compared to Verona Pharma's net margin of 0.00%. Agios Pharmaceuticals' return on equity of -2.51% beat Verona Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma	N/A	-79.54%	-43.49%
Agios Pharmaceuticals	1,845.92%	-2.51%	-2.26%

Do analysts rate VRNA or AGIO?

Verona Pharma currently has a consensus target price of $87.44, indicating a potential downside of 2.89%. Agios Pharmaceuticals has a consensus target price of $56.50, indicating a potential upside of 64.20%. Given Agios Pharmaceuticals' higher possible upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.10
Agios Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63

Does the media refer more to VRNA or AGIO?

In the previous week, Verona Pharma had 3 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 12 mentions for Verona Pharma and 9 mentions for Agios Pharmaceuticals. Verona Pharma's average media sentiment score of 1.26 beat Agios Pharmaceuticals' score of 1.01 indicating that Verona Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verona Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agios Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in VRNA or AGIO?

85.9% of Verona Pharma shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more volatility and risk, VRNA or AGIO?

Verona Pharma has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Which has stronger earnings and valuation, VRNA or AGIO?

Agios Pharmaceuticals has lower revenue, but higher earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma	$118.54M	61.60	-$54.37M	-$2.00	-45.03
Agios Pharmaceuticals	$37.04M	53.81	$673.72M	$11.24	3.06

Does the MarketBeat Community favor VRNA or AGIO?

Agios Pharmaceuticals received 153 more outperform votes than Verona Pharma when rated by MarketBeat users. However, 81.10% of users gave Verona Pharma an outperform vote while only 66.76% of users gave Agios Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Verona Pharma	Outperform Votes 339 81.10%	Underperform Votes 79 18.90%
Agios Pharmaceuticals	Outperform Votes 492 66.76%	Underperform Votes 245 33.24%

Summary

Agios Pharmaceuticals beats Verona Pharma on 10 of the 19 factors compared between the two stocks.